Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
Summary not available.
VolitionRx Limited (NYSE AMERICAN: VNRX) is set to host a Capital Markets Day on May 11, 2023, at 2 p.m. Eastern Time, in a hybrid format at the New York Stock Exchange and via live webcast. The event will feature presentations by the executive team and recognized experts in the field, including Dr. Andy Retter and veterinary oncologists Professor Heather Wilson-Robles and Dr. Sue Ettinger. Topics will include the company's corporate strategy, Nu.Q® technology applications in sepsis, and veterinary diagnostics. A Q&A session will follow the presentations. Interested attendees can register for the event virtually or contact for in-person attendance. The event will also be webcasted, with presentations available on Volition's website post-event. VolitionRx focuses on cost-effective blood tests for diagnosing and monitoring diseases like cancer.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported its full fiscal year 2022 results, highlighting a 240% revenue increase to approximately $300,000. The company secured global licensing agreements with Heska Corporation and IDEXX Laboratories for its Nu.Q® Vet Cancer Test, generating an upfront payment of $10 million and potential milestone payments up to $18 million. Cash and equivalents stood at $10.9 million as of December 31, 2022, after raising $8 million through a public offering. Volition continues to expand its intellectual property portfolio, holding 34 patent families and 97 granted patents. A conference call is scheduled for March 16, 2023, to discuss the results.
VolitionRx Limited (AMEX: VNRX) has announced a conference call scheduled for March 16, 2023, at 08:30 a.m. Eastern Time, to discuss its full fiscal year 2022 financial and operating results, along with a business update. CEO Cameron Reynolds, along with other executives, will address key events from 2022 and future milestones. A live audio webcast will be available on Volition's investor relations page, and a replay will be accessible until March 30, 2023. VolitionRx specializes in developing cost-effective blood tests for diagnosing and monitoring diseases using its proprietary Nu.Q® platform.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the completion of its underwritten public offering of 4,945,000 shares at $1.75 per share, yielding approximately $8.7 million in gross proceeds. The offering included full exercise of the underwriter's overallotment option. Net proceeds will be allocated for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions. The shares were issued under a previously filed shelf registration statement with the SEC. Newbridge Securities Corporation acted as the sole book-running manager for this offering.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced a public offering of 4,300,000 shares at $1.75 each, expected to generate approximately $7.525 million in gross proceeds. The closing of the offering is anticipated on February 22, 2023, pending customary conditions. The company plans to utilize the net proceeds for various purposes, including research, product development, clinical studies, and potential strategic acquisitions. Additionally, an underwriter has a 30-day option to purchase up to 645,000 additional shares to cover over-allotments. This offering follows a shelf registration statement with the SEC filed in September 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced an underwritten public offering of its common stock on February 16, 2023. The offering includes a 30-day option for the underwriter to purchase up to an additional 15% of the offered shares. Proceeds from the offering are earmarked for research, product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions. The final terms of the offering will be subject to market conditions and cannot be guaranteed. Newbridge Securities Corporation is the sole book-running manager for this offering.
VolitionRx Limited (NYSE American: VNRX) has announced the pre-order availability of its Nu.Q® Vet Cancer Test for veterinarians through Heska Corporation (NASDAQ: HSKA). This innovative test will be showcased at the 2023 Western Veterinary Conference in Las Vegas. The Nu.Q® test operates on Heska's Element i+® Immunodiagnostic Analyzer, providing rapid and accurate on-site testing for under $50, assisting in early cancer detection in dogs. The collaboration signifies a breakthrough in making Volition's Nucleosomics™ technology accessible at the point of care, enhancing veterinary care and patient outcomes. The commercial launch is targeted for early Q2 2023.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced participation in a webinar on January 26, 2023, focusing on the Nu.Q® Vet commercial strategy. Key speakers include CEO Dr. Tom Butera and Chief Medical Officer Dr. Heather Wilson Robles. The event aims to provide insights into the Nu.Q® Vet Cancer Test, a cost-effective blood test for early detection in dogs. Volition is exploring significant market opportunities in companion animal healthcare. The webinar will be recorded for later access. Volition develops blood tests for diagnosing diseases, leveraging its Nucleosomics™ platform.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the launch of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories reference laboratory network in the U.S. This innovative blood test is designed to detect cancer in older or at-risk dogs, leveraging Volition's Nucleosomics™ technology. IDEXX aims to use this test to enhance pet health and wellbeing by facilitating earlier diagnosis and treatment. With a significant potential market, this partnership is expected to expand Volition’s reach in the companion animal healthcare sector.